The Reproductive Infectious Disease Program has received CIHR funding to carry out the NOVA-HIV clinical trial. The goal of this study is to explore reduced dosing of the nonavalent HPV vaccine in women living with HIV. This multi-site phase IV clinical trial will carry on from our previous HPV in HIV studies. Investigators intend to begin recruiting for the NOVA-HIV study within the first half of 2023.
It is now known that the vast majority of cervical cancers are caused by HPV infection. Therefore, cervical cancer can be prevented through HPV vaccination. In young women without HIV, this vaccine has been shown to prevent HPV infection in those not previously infected with the 9 types of HPV that the vaccine protects against. However, there are very little data on nonavalent HPV vaccination among the 18 million women living with HIV globally, who constitute a population most vulnerable to HPV and cervical cancer.
This study will determine whether two doses of 9vHPV vaccine can be used in women living with HIV instead of three, and will examine additional aspects of HPV vaccination in WLWH including the immune response to three doses, vaccine safety and efficacy, and attitudes towards self-collected HPV samples in this population. These data will inform global public health policy and programming and will inform the global strategy for cervical cancer elimination.
Principal Investigator: Dr. Deborah Money, MD, FRCSC, Professor, Obstetrics & Gynecology, Medicine, SPPH, Clinician Scientist, Women’s Health Research Institute.
For further information please contact the Senior Research Manager Evelyn Maan: firstname.lastname@example.org